热门资讯> 正文

Keros Therapeutics开始要约回购高达1.944亿美元的股票

2025-10-20 18:26

Keros Therapeutics (NASDAQ:KROS) has commenced a cash tender offer to repurchase up to $194.4 million of common shares, at a purchase price of $17.75 per share. The Company expects to fund the tender offer from its existing cash and cash equivalents.
The tender offer, which is a part of its previously announced $375 million capital return program, will expire at 5:00 p.m. ET on Tuesday, November 18, 2025, unless extended or earlier terminated.
KROS +3.9% premarket to $14.37
Source: Press Release

More on Keros Therapeutics

Keros Therapeutics: A Potential Dart Throw
Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path
Keros jumps on plan to return $375M in excess capital
Keros gains Orphan Drug designation for Duchenne muscular dystrophy asset
Seeking Alpha’s Quant Rating on Keros Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。